Hadasit Bio-Holdings Ltd (HSITF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Hadasit Bio-Holdings Ltd (HSITF) with AI Score 44/100 (Weak). Hadasit Bio-Holdings Ltd is an Israeli biotechnology company focusing on developing therapeutics in oncology, regenerative medicine, and inflammatory diseases. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 18, 2026Hadasit Bio-Holdings Ltd (HSITF) Healthcare & Pipeline Overview
Hadasit Bio-Holdings Ltd, based in Israel, operates within the biotechnology sector, concentrating on oncology, regenerative medicine, and inflammatory diseases. The company's primary focus is the development of ProtAb, an immunotherapeutic monoclonal antibody aimed at treating autoimmune inflammatory diseases, positioning it in a niche market with significant growth potential.
Investment Thesis
Hadasit Bio-Holdings Ltd presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on ProtAb, an immunotherapeutic monoclonal antibody for autoimmune inflammatory diseases, offers potential for significant returns if clinical trials are successful and regulatory approvals are obtained. However, the company's small size and limited resources pose challenges to its ability to advance its pipeline independently. Key value drivers include successful clinical trial outcomes for ProtAb, strategic partnerships with larger pharmaceutical companies, and potential licensing agreements. The company's negative P/E ratio of -2.03 reflects its current lack of profitability, underscoring the speculative nature of the investment. Investors should carefully consider the risks associated with investing in early-stage biotechnology companies before making any investment decisions.
Based on FMP financials and quantitative analysis
Key Highlights
- Hadasit Bio-Holdings Ltd operates in the biotechnology industry, focusing on oncology, regenerative medicine, and inflammatory diseases.
- The company's primary product is ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases.
- Hadasit Bio-Holdings Ltd was founded in 2005 and is based in Jerusalem, Israel.
- The company has a market capitalization of $0.00B, indicating its small size and early stage of development.
- The company's P/E ratio is -2.03, reflecting its current lack of profitability.
Competitors & Peers
Strengths
- Focus on innovative immunotherapeutic antibodies.
- Potential for high-value licensing agreements.
- Expertise in autoimmune inflammatory diseases.
Weaknesses
- Small size and limited resources.
- Dependence on a single product candidate (ProtAb).
- Lack of profitability.
Catalysts
- Upcoming: Clinical trial results for ProtAb could drive significant stock movement.
- Upcoming: Potential partnerships with larger pharmaceutical companies could provide funding and expertise.
- Upcoming: Regulatory approvals for ProtAb in key markets would expand market access.
- Ongoing: Advancements in the company's research and development pipeline could lead to new therapeutic candidates.
Risks
- Potential: Clinical trial failures could negatively impact the company's prospects.
- Potential: Regulatory hurdles could delay or prevent the approval of ProtAb.
- Ongoing: Competition from larger, more established companies could limit market share.
- Ongoing: The company's small size and limited resources pose challenges to its ability to execute its strategy.
- Ongoing: Dependence on a single product candidate (ProtAb) increases the company's vulnerability to setbacks.
Growth Opportunities
- Growth opportunity 1: Successful clinical trials for ProtAb represent a significant growth opportunity for Hadasit Bio-Holdings Ltd. Positive clinical trial results would validate the efficacy and safety of ProtAb, increasing its market potential and attracting potential partners. The market for autoimmune disease therapeutics is substantial, with a global market size estimated at billions of dollars. The timeline for clinical trials can vary, but typically involves several phases over multiple years. Successful completion of each phase would represent a major milestone for the company.
- Growth opportunity 2: Strategic partnerships with larger pharmaceutical companies could provide Hadasit Bio-Holdings Ltd with access to funding, expertise, and resources needed to advance its pipeline. Collaborations with established players can accelerate the development and commercialization of ProtAb, increasing its market reach and potential revenue. The timeline for securing partnerships can vary, but typically involves negotiations and due diligence processes. Successful partnerships would significantly enhance the company's growth prospects.
- Growth opportunity 3: Expansion into new therapeutic areas represents another growth opportunity for Hadasit Bio-Holdings Ltd. By leveraging its expertise in antibody development, the company could explore new applications for its technology platform in other disease areas. The market for novel therapeutics is constantly evolving, with new opportunities emerging as scientific understanding advances. The timeline for expanding into new therapeutic areas would depend on the company's research and development efforts.
- Growth opportunity 4: Securing regulatory approvals for ProtAb in key markets, such as the United States and Europe, is essential for commercial success. Regulatory approvals would allow the company to market and sell ProtAb to a wider patient population, generating revenue and increasing its market share. The regulatory approval process can be lengthy and complex, requiring extensive clinical data and documentation. Successful regulatory approvals would represent a major milestone for the company.
- Growth opportunity 5: Out-licensing or selling ProtAb to a larger pharmaceutical company could provide Hadasit Bio-Holdings Ltd with a significant upfront payment and ongoing royalties. This strategy would allow the company to monetize its intellectual property and generate returns for its investors. The timeline for out-licensing or selling ProtAb would depend on market conditions and the level of interest from potential acquirers. A successful transaction would provide the company with financial resources to pursue other opportunities.
Opportunities
- Successful clinical trials for ProtAb.
- Strategic partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas.
Threats
- Clinical trial failures.
- Regulatory hurdles.
- Competition from larger, more established companies.
Competitive Advantages
- Proprietary antibody technology.
- Patents protecting its intellectual property.
- Expertise in antibody development and immunology.
About HSITF
Founded in 2005 and headquartered in Jerusalem, Israel, Hadasit Bio-Holdings Ltd is a biotechnology company dedicated to the discovery and development of innovative therapeutics. The company operates within the dynamic and competitive biotechnology industry, focusing on addressing unmet medical needs in oncology, regenerative medicine, and inflammatory diseases. Hadasit Bio-Holdings' core product is ProtAb, an immunotherapeutic monoclonal antibody designed for the treatment of autoimmune inflammatory diseases. ProtAb represents the company's commitment to developing targeted therapies that can improve patient outcomes. Hadasit Bio-Holdings operates primarily in Israel, engaging in research and development activities to advance its pipeline of therapeutic candidates. As a biotechnology company, Hadasit Bio-Holdings collaborates with research institutions and other industry partners to leverage scientific expertise and accelerate the development of its products. The company's small size, with only two employees, reflects its stage of development and focus on early-stage research and development activities. Hadasit Bio-Holdings aims to create value by identifying and developing promising therapeutic candidates, ultimately seeking partnerships or licensing agreements to bring its products to market.
What They Do
- Develops immunotherapeutic monoclonal antibodies.
- Focuses on treatments for autoimmune inflammatory diseases.
- Conducts research and development in oncology.
- Engages in regenerative medicine research.
- Operates in the biotechnology industry in Israel.
Business Model
- Develops and patents novel therapeutic antibodies.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
- Generates revenue through licensing fees and royalties.
Industry Context
Hadasit Bio-Holdings Ltd operates within the biotechnology industry, a sector characterized by rapid innovation, high risk, and significant potential for reward. The industry is driven by advancements in scientific research, increasing demand for novel therapies, and an aging global population. The competitive landscape includes established pharmaceutical companies, as well as numerous smaller biotechnology firms, all vying to develop and commercialize innovative treatments. Hadasit Bio-Holdings' focus on oncology, regenerative medicine, and inflammatory diseases aligns with key growth areas within the biotechnology industry. The company's success will depend on its ability to navigate the complex regulatory environment, secure funding, and effectively compete with larger, more established players.
Key Customers
- Pharmaceutical companies seeking novel therapeutic candidates.
- Patients with autoimmune inflammatory diseases.
- Healthcare providers treating autoimmune inflammatory diseases.
Financials
Chart & Info
Hadasit Bio-Holdings Ltd (HSITF) stock price: Price data unavailable
Latest News
No recent news available for HSITF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HSITF.
Price Targets
Wall Street price target analysis for HSITF.
MoonshotScore
What does this score mean?
The MoonshotScore rates HSITF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Yuval Adar
Managing Director
Yuval Adar is the Managing Director of Hadasit Bio-Holdings Ltd. His background includes experience in managing small teams and overseeing the operations of the company. Information regarding his specific educational background and previous roles is not available. As the head of Hadasit Bio-Holdings, Yuval Adar is responsible for guiding the company's strategic direction and overseeing its research and development activities.
Track Record: Under Yuval Adar's leadership, Hadasit Bio-Holdings Ltd has focused on the development of ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. Specific milestones and achievements under his leadership are not available. His focus is on advancing the company's pipeline and seeking strategic partnerships to support its growth.
HSITF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Hadasit Bio-Holdings Ltd may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading may be more speculative. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to the same rigorous listing standards and regulatory oversight, resulting in higher risks for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure requirements.
- Potential for fraud or manipulation.
- Lack of liquidity.
- Higher price volatility.
- Limited regulatory oversight.
- Verify the company's management team and their track record.
- Review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Confirm the company's registration and compliance status.
- Company's focus on biotechnology and therapeutic development.
- Development of ProtAb, an immunotherapeutic monoclonal antibody.
- Company's founding in 2005, indicating some operational history.
HSITF Healthcare Stock FAQ
What does Hadasit Bio-Holdings Ltd do?
Hadasit Bio-Holdings Ltd is a biotechnology company based in Israel, focused on developing novel therapeutics in the areas of oncology, regenerative medicine, and inflammatory diseases. Their primary focus is on ProtAb, an immunotherapeutic monoclonal antibody designed to treat autoimmune inflammatory diseases. The company aims to develop and commercialize innovative treatments that address unmet medical needs in these therapeutic areas, ultimately improving patient outcomes through targeted therapies.
What do analysts say about HSITF stock?
As of 2026-03-18, there is no available analyst coverage for Hadasit Bio-Holdings Ltd (HSITF). This is likely due to the company's small market capitalization, OTC listing, and early stage of development. Investors should conduct their own thorough research and consider the risks associated with investing in small-cap biotechnology companies before making any investment decisions. The lack of analyst coverage underscores the speculative nature of the investment.
What are the main risks for HSITF?
Hadasit Bio-Holdings Ltd faces several key risks, including clinical trial failures, regulatory hurdles, competition from larger companies, and limited financial resources. Clinical trial failures could halt the development of ProtAb and negatively impact the company's prospects. Regulatory hurdles could delay or prevent the approval of ProtAb, limiting its market access. Competition from larger, more established companies could limit market share and pricing power. The company's small size and limited resources pose challenges to its ability to execute its strategy and compete effectively.
What are the key factors to evaluate for HSITF?
Hadasit Bio-Holdings Ltd (HSITF) currently holds an AI score of 44/100, indicating low score. Key strength: Focus on innovative immunotherapeutic antibodies.. Primary risk to monitor: Potential: Clinical trial failures could negatively impact the company's prospects.. This is not financial advice.
How frequently does HSITF data refresh on this page?
HSITF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HSITF's recent stock price performance?
Recent price movement in Hadasit Bio-Holdings Ltd (HSITF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on innovative immunotherapeutic antibodies.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HSITF overvalued or undervalued right now?
Determining whether Hadasit Bio-Holdings Ltd (HSITF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HSITF?
Before investing in Hadasit Bio-Holdings Ltd (HSITF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited due to the company's OTC listing and limited disclosure requirements.
- AI analysis is pending and may provide further insights.